Disease specific therapies in leukodystrophies and leukoencephalopathies

Guy Helman¹, Keith Van Haren², Joshua L Bonkowsky³, Genevieve Bernard⁴, Amy Pizzino², Nancy Braverman⁵, Dean Suhr⁶, Marc C Patterson⁷, S Ali Fatemi⁸, Jeff Leonard⁹, Marjo S van der Knaap¹⁰, Stephen A Back¹¹, Stephen Damiani¹², Steven A Goldman¹³, Asako Takanohashi¹⁴, Magdalena Petryniak¹⁵, David Rowitch¹⁶, Albee Messing¹⁷, Lawrence Wrabetz¹⁸, Raphael Schiffmann¹⁹, Florian Eichler²⁰, Maria L Escolar²¹, Adeline Vanderver²²; GLIA Consortium

Affiliations

¹ Department of Neurology, Children's National Health System, Washington, DC, USA.
² Department of Neurology, Lucile Packard Children's Hospital and Stanford University School of Medicine, Stanford, CA, USA.
³ Department of Pediatrics and Neurology, University of Utah School of Medicine, Salt Lake City, UT, USA.
⁴ Department of Pediatrics, Montreal Children's Hospital/McGill University Health Center, Montreal, Canada; Department of Neurology and Neurosurgery, Montreal Children's Hospital/McGill University Health Center, Montreal, Canada.
⁵ Department of Human Genetics and Pediatrics, McGill University and the Montreal Children's Hospital Research Institute, Montreal, Canada.
⁶ MLD Foundation, USA.
⁷ Department of Neurology, Mayo Clinic, Rochester, MN, USA; Department of Pediatrics and Medical Genetics, Mayo Clinic, Rochester, MN, USA.
⁸ The Moser Center for Leukodystrophies and Neurogenetics Service, The Kennedy Krieger Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA.
⁹ The PMD Foundation, USA.
¹⁰ Department of Child Neurology, VU University Medical Center, and Neuroscience Campus Amsterdam, Amsterdam, The Netherlands.
¹¹ Department of Pediatrics and Neurology, Oregon Health and Science University, Portland, OR, USA.
¹² Mission Massimo Foundation Inc., Melbourne, VIC, Australia; Mission Massimo Foundation Inc., Los Angeles, CA, USA.
¹³ Center for Translational Neuromedicine and the Department of Neurology of the University of Rochester Medical Center, Rochester, NY, USA.
¹⁴ Center for Genetic Medicine Research, Children's National Health System, Washington, DC USA.
¹⁵ Department of Pediatrics, Papé Family Pediatric Research Institute, Oregon Health and Science University, Portland, OR, USA.
¹⁶ Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
¹⁷ Waisman Center and Department of Comparative Biosciences, University of Wisconsin-Madison, Madison, WI, USA.
¹⁸ Department of Neurology, Hunter James Kelly Research Institute-HJRKI, University of Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA; Department of Biochemistry, Hunter James Kelly Research Institute-HJRKI, University of Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA.
¹⁹ Institute of Metabolic Disease, Baylor Research Institute, Dallas, TX, USA.
²⁰ Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
²¹ Department of Pediatrics, University of Pittsburgh, One Children's Hospital Drive, Pittsburgh, PA, USA.
²² Department of Neurology, Children's National Health System, Washington, DC, USA; Center for Genetic Medicine Research, Children's National Health System, Washington, DC USA; Department of Integrated Systems Biology, George Washington University School of Medicine, Washington, DC, USA. Electronic address: avanderv@childrensnational.org.

PMID: 25684057
PMCID: PMC4390468
DOI: 10.1016/j.ymgme.2015.01.014

Disease specific therapies in leukodystrophies and leukoencephalopathies

Guy Helman et al. Mol Genet Metab. 2015 Apr.

. 2015 Apr;114(4):527-36.

doi: 10.1016/j.ymgme.2015.01.014. Epub 2015 Feb 7.

Authors

Affiliations

¹ Department of Neurology, Children's National Health System, Washington, DC, USA.
² Department of Neurology, Lucile Packard Children's Hospital and Stanford University School of Medicine, Stanford, CA, USA.
³ Department of Pediatrics and Neurology, University of Utah School of Medicine, Salt Lake City, UT, USA.
⁴ Department of Pediatrics, Montreal Children's Hospital/McGill University Health Center, Montreal, Canada; Department of Neurology and Neurosurgery, Montreal Children's Hospital/McGill University Health Center, Montreal, Canada.
⁵ Department of Human Genetics and Pediatrics, McGill University and the Montreal Children's Hospital Research Institute, Montreal, Canada.
⁶ MLD Foundation, USA.
⁷ Department of Neurology, Mayo Clinic, Rochester, MN, USA; Department of Pediatrics and Medical Genetics, Mayo Clinic, Rochester, MN, USA.
⁸ The Moser Center for Leukodystrophies and Neurogenetics Service, The Kennedy Krieger Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA.
⁹ The PMD Foundation, USA.
¹⁰ Department of Child Neurology, VU University Medical Center, and Neuroscience Campus Amsterdam, Amsterdam, The Netherlands.
¹¹ Department of Pediatrics and Neurology, Oregon Health and Science University, Portland, OR, USA.
¹² Mission Massimo Foundation Inc., Melbourne, VIC, Australia; Mission Massimo Foundation Inc., Los Angeles, CA, USA.
¹³ Center for Translational Neuromedicine and the Department of Neurology of the University of Rochester Medical Center, Rochester, NY, USA.
¹⁴ Center for Genetic Medicine Research, Children's National Health System, Washington, DC USA.
¹⁵ Department of Pediatrics, Papé Family Pediatric Research Institute, Oregon Health and Science University, Portland, OR, USA.
¹⁶ Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
¹⁷ Waisman Center and Department of Comparative Biosciences, University of Wisconsin-Madison, Madison, WI, USA.
¹⁸ Department of Neurology, Hunter James Kelly Research Institute-HJRKI, University of Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA; Department of Biochemistry, Hunter James Kelly Research Institute-HJRKI, University of Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA.
¹⁹ Institute of Metabolic Disease, Baylor Research Institute, Dallas, TX, USA.
²⁰ Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
²¹ Department of Pediatrics, University of Pittsburgh, One Children's Hospital Drive, Pittsburgh, PA, USA.
²² Department of Neurology, Children's National Health System, Washington, DC, USA; Center for Genetic Medicine Research, Children's National Health System, Washington, DC USA; Department of Integrated Systems Biology, George Washington University School of Medicine, Washington, DC, USA. Electronic address: avanderv@childrensnational.org.

PMID: 25684057
PMCID: PMC4390468
DOI: 10.1016/j.ymgme.2015.01.014

Abstract

Leukodystrophies are a heterogeneous, often progressive group of disorders manifesting a wide range of symptoms and complications. Most of these disorders have historically had no etiologic or disease specific therapeutic approaches. Recently, a greater understanding of the pathologic mechanisms associated with leukodystrophies has allowed clinicians and researchers to prioritize treatment strategies and advance research in therapies for specific disorders, some of which are on the verge of pilot or Phase I/II clinical trials. This shifts the care of leukodystrophy patients from the management of the complex array of symptoms and sequelae alone to targeted therapeutics. The unmet needs of leukodystrophy patients still remain an overwhelming burden. While the overwhelming consensus is that these disorders collectively are symptomatically treatable, leukodystrophy patients are in need of advanced therapies and if possible, a cure.

Keywords: Care; Consensus; Leukodystrophy; Outcomes; Prevention; Therapy.

PubMed Disclaimer

Conflict of interest statement

6. Conflicts of Interest:

MCP: Editorial: Journal of Child Neurology, Child Neurology Open (Editor-in-Chief), Journal of Inherited Metabolic Disease (Editor). Otherwise authors report no conflict of interest.

References

1. Parikh S, Bernard G, Leventer R, van der Knaap M, Van Hove J, Pizzino A, McNeill N, Helman G, Simons C, Rizzo W, Patterson M, Taft R, Vanderver A. A clinical approach to the diagnosis of patients with leukodystrophies and genetic leukoencephalopathies. Molecular Genetics and Metabolism. 2014 In press. - PMC - PubMed
1. Vanderver A, Prust M, Tonduti D, Mochel F, Hussey H, Helman G, Garbern J, Eichler F, Labauge P, Aubourg P, Rodriguez D, Patterson M, Van Hove J, Schmidt J, Wolf N, Boespflug-Tanguy O, Schiffmann R, van der Knaap M. Case Definition and Classification of Leukodystrophies and Leukoencephalopathies. Molecular Genetics and Metabolism. 2014 In Press. - PMC - PubMed
1. Van Haren K, Bonkowsky J, Bernard G, Murphy J, Pizzino A, Helman G, Suhr D, Waggoner J, Hobson D, Vanderver A, Patterson M. Consensus Statement on Preventive and Symptomatic Care of Leukodystrophy Patients. 2014 In Press. - PubMed
1. Engelen M, Kemp S, de Visser M, van Geel BM, Wanders RJ, Aubourg P, Poll-The BT. X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management. Orphanet journal of rare diseases. 2012;7:51. - PMC - PubMed
1. Peters C, Charnas LR, Tan Y, Ziegler RS, Shapiro EG, DeFor T, Grewal SS, Orchard PJ, Abel SL, Goldman AI, Ramsay NK, Dusenbery KE, Loes DJ, Lockman LA, Kato S, Aubourg PR, Moser HW, Krivit W. Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood. 2004;104:881–888. - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Disease specific therapies in leukodystrophies and leukoencephalopathies

Affiliations

Disease specific therapies in leukodystrophies and leukoencephalopathies

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical